# CFI-402411

Source: https://onco.cc/drugs/cfi-402411/  
OnCo record `cfi-402411` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CFI-402411 is an experimental small molecule from Treadwell Therapeutics, in phase 1 trials for advanced solid tumours; its current status is not stated.

## Summary

CFI-402411 is a small molecule from Treadwell Therapeutics. An oral small-molecule inhibitor of HPK1, tested alone and with pembrolizumab in advanced solid tumours. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Company pipeline lists TWT-101 as Phase 1 'Actively recruiting', but the registry record NCT04521413 shows overall status UNKNOWN (registered as phase 1/2); the company pipeline page appears out of date. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: CFI-402411
- Modality: Small molecule
- Mechanism: An oral small-molecule inhibitor of HPK1, tested alone and with pembrolizumab in advanced solid tumours.

## Sources

- Treadwell Therapeutics: treadwelltx.com: https://treadwelltx.com/pipeline/
- Treadwell Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT04521413
- ClinicalTrials.gov: trials of CFI-402411: https://clinicaltrials.gov/search?intr=CFI-402411

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [HPK1 (MAP4K1)](https://onco.cc/targets/hpk1/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)
- trials: [Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies](https://onco.cc/trials/nct04521413/)

---
JSON: https://onco.cc/api/v1/entities/cfi-402411.json